Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment

Journal of Public Economics

Volumn 95, Issue 7-8, 2011, Pages 624-638

  Brekke, Kurt R ^a   Holmas, Tor Helge ^b   Straume, Odd Rune ^c,d  

^a NORWEGIAN SCHOOL OF ECONOMICS   (Norway)

^b Uni Rokkan Centre   (Norway)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Generic competition; Pharmaceuticals; Regulation

Indexed keywords

EID: 79955030806     PISSN: 00472727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpubeco.2010.11.015     Document Type: Article

References (35)

1. Aronsson T., Bergman M.A., Rudholm N. The impact of generic drug competition on brand name market shares - evidence from micro data. Review of Industrial Organization 2001, 19:425-435.
2. Bardey D., Bommier A., Jullien B. Retail price regulation and innovation: reference pricing in the pharmaceutical industry. Journal of Health Economics 2010, 29:303-316.
3. Baum C.F., Schaffer M.E., Stillman S. Enhanced routines for instrumental variables/GMM estimation and testing. Boston College Economics Working Paper No. 667 2007.
4. Bergman M.A., Rudholm N. The relative importance of actual and potential competition: empirical evidence from the pharmaceuticals market. Journal of Industrial Economics 2003, 51:455-467.
5. Bertrand M., Duflo E., Mullainathan S. How much should we trust differences-in-differences estimates?. Quarterly Journal of Economics 2004, 119:249-275.
6. Brekke K.R., Straume O.R. Pharmaceutical patents: incentives for research and development or marketing?. Southern Economic Journal 2009, 76:351-374.
7. Brekke K.R., Königbauer I., Straume O.R. Reference pricing of pharmaceuticals. Journal of Health Economics 2007, 26:613-642.
8. Brekke K.R., Grasdal A.L., Holmås T.H. Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation?. European Economic Review 2009, 53:170-185.
9. Ching A.T. Consumer learning and heterogeneity: dynamics of demand for prescription drugs after patent expiration. International Journal of Industrial Organization 2010, 28:619-638.
10. Ching A.T. A dynamic oligopoly structural model of the prescription drug market after patent expiration. International Economic Review 2010, 51:1175-1207.
11. Danzon P.M. Pharmaceutical price regulation: national policies versus global interests 1997, American Enterprise Institute Press, Washington.
12. Danzon P.M., Chao L.-W. Does regulation drive out competition in pharmaceutical markets?. Journal of Law & Economics 2000, 43:311-357.
13. Danzon P.M., Ketcham J.D. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, the Netherlands and New Zealand. Frontiers in Health Policy Research 2004, vol. 7. National Bureau of Economic Research and MIT Press. D.M. Cutler, A.M. Garber (Eds.).
14. Danzon P.M., Lui H. Reference pricing and physician drug budgets: the German experience in controlling pharmaceutical expenditures. Working Paper 1996, The Wharton School, University of Pennsylvania.
15. Ellison S.F, Cockburn I., Griliches A., Hausman J. Characteristics of demand for pharmaceutical products: An examination of four cephalosporins. RAND Journal of Economics 1997, 28:426-446.
16. Frank R.G., Newhouse J.P. Should drug prices be negotiated under part D Of Medicare? And if so, how?. Health Affairs 2008, 27:33-43.
17. Frank R.G., Salkever D.S. Generic entry and the market for pharmaceuticals. Journal of Economics & Management Strategy 1997, 6:75-90.
18. Gallini N. The economics of patents: lessons from recent U.S. patent reform. Journal of Economics Perspectives 2002, 16:131-154.
19. Grabowski H.G., Vernon J. Brand loyalty, entry, and price competition in pharmaceuticals after the 984 Drug Act. Journal of Law and Economics 1992, 35:331-350.
20. Hellerstein J.K. The importance of the physician in the generic versus trade-name prescription decision. RAND Journal of Economics 1998, 29:108-136.
21. Kaiser, U., Mendez, S.J., Rønde, T., 2010. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark. Mimeo.
22. Kanavos P. Overview of pharmaceutical pricing and reimbursement regulation in Europe. Commission of the European Communities, Dg Enterprise, November 2001.
23. Königbauer I. Advertising and generic market entry. Journal of Health Economics 2007, 26:286-305.
24. Kyle M. Pharmaceutical price controls and entry strategies. Review of Economics and Statistics 2007, 89:88-99.
25. Lopez-Casasnovas G., Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000, 54:87-123.
26. Miraldo M. Reference pricing and firms' pricing strategies. Journal of Health Economics 2009, 28:176-197.
27. Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?. RAND Journal of Economics 2002, 33:469-487.
28. Saha A., Grabowski H.G., Birnbaum H., Greenberg P., Bizan O. Generic competition in the U.S. pharmaceutical industry. International Journal of the Economics of Business 2006, 13:15-38.
29. Sakakibara M., Branstetter L. Do stronger patents induce more innovation? Evidence from the 1988 Japanese patent law reforms. RAND Journal of Economics 2001, 32:77-100.
30. Schaffer M.E. xtivreg2: Stata Module to Perform Extended IV/2SLS, GMM and AC/HAC, LIML and K-class Regression for Panel Data Models 2007.
31. Scherer F.M. The pharmaceutical industry. Handbook of Health Economics 2000, Elsevier, North Holland, Amsterdam, Chapter 25. A.J. Cuyler, J.P. Newhouse (Eds.).
32. Scott Morton F.M. Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization 2000, 18:1085-1104.
33. Shleifer A. A theory of yardstick competition. RAND Journal of Economics 1985, 16:319-327.
34. Staiger D., Stock J.H. Instrumental variables regression with weak instruments. Econometrica 1997, 65(3):557-586.
35. Wooldridge J.M. Econometric analysis of cross section and panel data 2002, the MIT Press, Cambridge MA.